PCRX
Pacira BioSciences, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$25.35-1.02%
Price as of Jul 20, 2026
PCRX growth
Pacira BioSciences, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +4.6%
- EBITDA
- +322.5%
- EBIT
- +126.8%
- EPS
- +105.4%
- Free cash flow
- -16.7%
- Operating cash flow
- -19.1%
Forward estimates
- Revenue
- +13.6%
- EBITDA
- +1.2%
- EPS
- +2588.3%
Three-year CAGR
- Revenue
- +2.9%
- EBITDA
- -4.4%
- EBIT
- -17.8%
- Net income
- -23.8%
- EPS
- -23.0%
- Free cash flow
- +5.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.